1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > MediPoint: Viscosupplementation - Global Analysis and Market Forecasts

MediPoint: Viscosupplementation - Global Analysis and Market Forecasts

Summary

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. Growth of the viscosupplementation market will be highest in the US and the Asia-Pacific (APAC) region, where there is a significant pent-up demand for early intervention in the management of OA.

The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids.

Highlights

Key Questions Answered

- Future growth in the viscosupplementation market lies in the one-injection segment. What are the current adoption trends in different geographies? How will one-injection segment drive the market revenue growth in the upcoming years?
- In the US, some commercial insurers have completely excluded viscosupplementation treatment from their coverage. Even when the criteria for coverage have clearly been met by the patient, denials are common. Has this impacted the procedure volume growth in the US viscosupplementation market?
- Reimbursement is the single greatest barrier to the market growth for viscosupplementation procedures. How does the current payer mix look like in different countries?
- In recent years, there has been an expansion in the use of intra-articular HA viscosupplementation for treating OA at hips, shoulders, and other small joints. What are the current adoption trends in different regions?
- Because the most prevalent treatment regimen varies from region to region, the competitive landscape in the viscosupplementation space can be quite different across the geographies covered in this report. Who are the leading players in the viscosupplementation market in different countries?

Reasons to buy

- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table Of Contents

MediPoint: Viscosupplementation - Global Analysis and Market Forecasts
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 13
1.2 List of Figures 17
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
3 Treatment Modalities Overview 22
3.1 Treatment Paradigm 22
3.1.1 Physical Therapies 22
3.1.2 Medications 22
3.1.3 Hyaluronic Acid Viscosupplementation 23
3.1.4 Surgical Intervention 25
4 Industry Overview 26
4.1 Procedural Trends 26
4.1.1 Overview 26
4.1.2 US 30
4.1.3 5EU 33
4.1.4 Asia-Pacific 37
4.1.5 South America 42
4.2 Market Access 45
4.2.1 US 45
4.2.2 5EU 46
4.2.3 Asia-Pacific 47
4.2.4 South America 47
4.3 Reimbursement 48
4.3.1 US 48
4.3.2 5EU 52
4.3.3 Asia-Pacific 58
4.3.4 South America 61
4.4 Mergers and Acquisitions/Key Partnerships 62
4.4.1 Meda AB Acquires Rottapharm|Medaus for $3.1 Billion (October 2014) 62
4.4.2 Founders of Anteis Establish Aptissen (March 2014) 63
4.4.3 Bioventus Acquires Durolane Assets from Galderma (February 2014) 63
4.4.4 Zimmer to Combine with Biomet in a Transaction Valued at $13.35 Billion (April 2014) 63
4.4.5 Johnson and Johnson Acquires Synthes for $19.7 Billion (June 2012) 64
5 Market Drivers, Opportunities, and Barriers 65
5.1 Driver: Rising Prevalence of OA 65
5.2 Driver: Multimodal Treatment Paradigm for OA 66
5.3 Driver: Viscosupplementation Delays Total Knee Replacement 67
5.4 Driver: Side Effects of NSAIDs, Corticosteroids, and Narcotics 68
5.5 Driver: Direct-To-Consumer Marketing 70
5.6 Opportunity: Expanding Indications 71
5.7 Opportunity: New-Generation HA Derivatives 72
5.8 Opportunity: Increased Use After Arthroscopic Surgeries 74
5.9 Opportunity: Self-Pay Market 74
5.10 Opportunity: Emerging Countries 76
5.11 Barrier: Unfavorable Reimbursement Scenario 76
5.12 Barrier: Pricing Erosion 77
5.13 Barrier: Cost-Effective Pharmacological Therapies 78
5.14 Barrier: Will The Rising Popularity of PRP Injection Impact the Viscosupplementation Market? 78
5.15 Barrier: Cost-Conscious Patients in Emerging Countries 81
6 Unmet Needs 83
6.1 Lack of Consensus on Clinical Efficacy of Viscosupplementation in Knee OA 83
6.2 Insufficient Evidence to Prove the Clinical Efficacy of Viscosupplementation in Other Joints 85
6.3 Better Understanding of the Basic Science 87
6.4 Ultrasound-Guided Injection 90
7 Competitive Assessment 92
7.1 Major Viscosupplementation Products 92
7.1.1 Adant 92
7.1.2 Arthrum 93
7.1.3 Curavisc 93
7.1.4 Durolane 94
7.1.5 Euflexxa 95
7.1.6 Fermathron 96
7.1.7 Gel-One 97
7.1.8 Go-On 98
7.1.9 Hyalgan 99
7.1.10 Hyalubrix and HyalOne 100
7.1.11 Jonexa 101
7.1.12 NeoVisc 102
7.1.13 Orthovisc and Monovisc 103
7.1.14 Ostenil 104
7.1.15 Recosyn 105
7.1.16 RenehaVis 106
7.1.17 Supartz/ARTZ 107
7.1.18 Suplasyn 108
7.1.19 Suvenyl 109
7.1.20 Synocrom 110
7.1.21 Synolis V-A 110
7.1.22 Synovial 111
7.1.23 Synvisc and Synvisc-One 112
7.2 Other Viscosupplementation Products 114
8 Pipeline Products 116
8.1 Overview 116
8.2 Gel-Syn (IBSA Institut Biochimique S.A.) 117
8.3 Cingal (Anika Therapeutics) 117
8.4 Hydros-TA (Carbylan Therapeutics) 118
8.5 Additional Indication for Synvisc-One (Sanofi) 119
8.6 Hymovis (Fidia Farmaceutici S.p.A.) 119
8.7 HA-NSAID Conjugates (Seikagaku Corporation) 119
8.8 Additional Indication for Supartz/ARTZ (Seikagaku Corporation) 120
8.9 Clodronate-HA Conjugates (Abiogen Pharma) 120
9 Current and Future Players 121
9.1 Trends in Corporate Strategy 121
9.2 Major Manufacturers 122
9.2.1 Anika Therapeutics 122
9.2.2 Chugai Pharmaceutical 124
9.2.3 Ferring Pharmaceuticals 126
9.2.4 Fidia Farmaceutici S.p.A. 128
9.2.5 Meda AB 130
9.2.6 Sanofi 132
9.2.7 Seikagaku Corporation 135
9.3 Major Marketing Partners 137
9.3.1 Bioventus 137
9.3.2 DePuy Synthes 139
9.3.3 Zimmer-Biomet 141
10 Market Outlook 144
10.1 Market Share Analysis by Country 144
10.1.1 US Market 144
10.1.2 5EU Market 145
10.1.3 Asia-Pacific Market 148
10.1.4 Brazil Market 150
10.2 By Market Segment 150
10.2.1 One-Injection Segment 150
10.2.2 Three-Injection Segment 151
10.2.3 Five-Injection Segment 152
10.3 By Geography 154
10.3.1 Overview 154
10.3.2 US 158
10.3.3 France 161
10.3.4 Germany 163
10.3.5 Italy 165
10.3.6 Spain 167
10.3.7 UK 169
10.3.8 Japan 171
10.3.9 Brazil 173
10.3.10 China 175
10.3.11 India 178
11 Appendix 181
11.1 Bibliography 181
11.2 Abbreviations 187
11.3 Report Methodology 191
11.3.1 Overview 191
11.3.2 Coverage 191
11.3.3 Secondary Research 191
11.3.4 Forecasting Methodology 192
11.3.5 Primary Research — Key Opinion Leader Interviews 193
11.3.6 Expert Panel Validation 193
11.4 Physicians and Specialists Included in This Study 194
11.5 About the Authors 197
11.5.1 Analysts 197
11.5.2 Jim Coutcher, MS, Global Head of Healthcare 198
11.6 About MediPoint 199
11.7 About GlobalData 199
11.8 Disclaimer 200

1.1 List of Tables
Table 1: US Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021 31
Table 2: US Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 32
Table 3: 5EU Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021 34
Table 4: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 37
Table 5: APAC Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021 39
Table 6: APAC Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 42
Table 7: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021 43
Table 8: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 44
Table 9: Differences Between US FDA Approval and EU CE Marking of Medical Devices 46
Table 10: US Medicare ASPs* for Viscosupplementation Products (2014-2015) 49
Table 11: Potential Clinical Benefits of HA-NSAIDs Conjugates 73
Table 12: Current CPGs on the Use of Viscosupplementation in Joints Other Than the Knee 86
Table 13: Product Profile - Adant 92
Table 14: Product Profile - Arthrum 93
Table 15: Product Profile - Curavisc 94
Table 16: Product Profile - Durolane 95
Table 17: Product Profile - Euflexxa 96
Table 18: Product Profile - Fermathron 97
Table 19: Product Profile - Gel-One 98
Table 20: Product Profile - Go-On 99
Table 21: Product Profile - Hyalgan 100
Table 22: Product Profile - Hyalubrix and HyalOne 101
Table 23: Product Profile - Jonexa 102
Table 24: Product Profile - NeoVisc 103
Table 25: Product Profile - Orthovisc and Monovisc 104
Table 26: Product Profile - Ostenil 105
Table 27: Product Profile - Recosyn 106
Table 28: Product Profile - RenehaVis 107
Table 29: Product Profile - Supartz/ARTZ 108
Table 30: Product Profile - Suplasyn 109
Table 31: Product Profile - Suvenyl 109
Table 32: Product Profile - Synocrom 110
Table 33: Product Profile - Synolis V-A 111
Table 34: Product Profile - Synovial 112
Table 35: Product Profile - Synvisc and Synvisc-One 113
Table 36: Other Viscosupplementation Products in the Global Market, 2015 114
Table 37: Major Pipeline Products in the Viscosupplementation Market, 2015 116
Table 38: Company Profile - Anika Therapeutics 122
Table 39: Anika Therapeutics' Viscosupplementation Portfolio Assessment, 2015 123
Table 40: SWOT Analysis - Anika Therapeutics 124
Table 41: Company Profile - Chugai Pharmaceutical 125
Table 42: Chugai Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015 126
Table 43: SWOT Analysis - Chugai Pharmaceutical 126
Table 44: Company Profile - Ferring Pharmaceuticals 127
Table 45: Ferring Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015 127
Table 46: SWOT Analysis - Ferring Pharmaceuticals 128
Table 47: Company Profile - Fidia Farmaceutici S.p.A. 129
Table 48: Fidia Farmaceutici S.p.A.'s Viscosupplementation Portfolio Assessment, 2015 130
Table 49: SWOT Analysis - Fidia Farmaceutici S.p.A. 130
Table 50: Company Profile - Meda AB 131
Table 51: Meda AB's Viscosupplementation Portfolio Assessment, 2015 132
Table 52: SWOT Analysis - Meda AB 132
Table 53: Company Profile - Sanofi 133
Table 54: Sanofi's Viscosupplementation Portfolio Assessment, 2015 134
Table 55: SWOT Analysis - Sanofi 134
Table 56: Company Profile - Seikagaku Corporation 135
Table 57: Seikagaku Corporation's Viscosupplementation Portfolio Assessment, 2015 136
Table 58: SWOT Analysis - Seikagaku Corporation 137
Table 59: Company Profile - Bioventus 138
Table 60: Bioventus' Viscosupplementation Portfolio Assessment, 2015 138
Table 61: SWOT Analysis - Bioventus 139
Table 62: Company Profile - DePuy Synthes 140
Table 63: DePuy Synthes' Viscosupplementation Portfolio Assessment, 2015 141
Table 64: SWOT Analysis - DePuy Synthes 141
Table 65: Company Profile - Zimmer-Biomet 142
Table 66: Zimmer-Biomet's Viscosupplementation Portfolio Assessment, 2015 143
Table 67: SWOT Analysis - Zimmer-Biomet 143
Table 68: Global Viscosupplementation One-Injection Market Revenue ($m), by Region, 2012-2021 151
Table 69: Global Viscosupplementation Three-Injection Market Revenue ($m), by Region, 2012-2021 152
Table 70: Global Viscosupplementation Five-Injection Market Revenue ($m), by Region, 2012-2021 153
Table 71: Global Viscosupplementation Market Revenue ($m), by Segment, 2011-2020 154
Table 72: Global Viscosupplementation Market Revenue ($m), by Geography, 2012-2021 157
Table 73: US Viscosupplementation Market Revenue ($m), 2012-2021 159
Table 74: France Viscosupplementation Market Revenue ($m), 2012-2021 161
Table 75: Germany Viscosupplementation Market Revenue ($m), 2012-2021 164
Table 76: Italy Viscosupplementation Market Revenue ($m), 2012-2021 166
Table 77: Spain Viscosupplementation Market Revenue ($m), 2012-2021 168
Table 78: UK Viscosupplementation Market Revenue ($m), 2012-2021 170
Table 79: Japan Viscosupplementation Market Revenue ($m), 2012-2021 172
Table 80: Brazil Viscosupplementation Market Revenue ($m), 2012-2021 174
Table 81: China Viscosupplementation Market Revenue ($m), 2012-2021 176
Table 82: India Viscosupplementation Market Revenue ($m), 2012-2021 179

1.2 List of Figures
Figure 1: US Physician Adoption Trend for Viscosupplementation, by Specialty 26
Figure 2: US Procedure Trends for Viscosupplementation, by Joint Type, 2014 32
Figure 3: US Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014 33
Figure 4: US Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 33
Figure 5: 5EU Procedure Trends for Viscosupplementation, by Joint Type, 2014 35
Figure 6: 5EU Adoption Trends for Viscosupplementation, by Treatment Regimen, 2014 36
Figure 7: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 37
Figure 8: APAC Procedure Trends for Viscosupplementation, by Joint Type, 2014 39
Figure 9: APAC Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014 41
Figure 10: APAC Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 42
Figure 11: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2014 43
Figure 12: Brazil Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014 44
Figure 13: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021 45
Figure 14: US Medicare Reimbursement Trend for Viscosupplementation, 2014-2015* 49
Figure 15: Payer Mix for Viscosupplementation in the US, 2014 50
Figure 16: Payer Mix for Viscosupplementation in France, 2014 53
Figure 17: Payer Mix for Viscosupplementation in Germany, 2014 55
Figure 18: Payer Mix for Viscosupplementation in Italy, 2014 56
Figure 19: Payer Mix for Viscosupplementation in Spain, 2014 57
Figure 20: Payer Mix for Viscosupplementation in the UK, 2014 58
Figure 21: Payer Mix for Viscosupplementation in Japan, 2014 59
Figure 22: Payer Mix for Viscosupplementation in China, 2014 60
Figure 23: Payer Mix for Viscosupplementation in India, 2014 61
Figure 24: Payer Mix for Viscosupplementation in Brazil, 2014 62
Figure 25: US Viscosupplementation Market Share, by Product, 2014 145
Figure 26: France Viscosupplementation Market Share, by Product, 2014 145
Figure 27: Germany Viscosupplementation Market Share, by Product, 2014 146
Figure 28: Italy Viscosupplementation Market Share, by Product, 2014 146
Figure 29: Spain Viscosupplementation Market Share, by Product, 2014 147
Figure 30: UK Viscosupplementation Market Share, by Product, 2014 147
Figure 31: Japan Viscosupplementation Market Share, by Product, 2014 148
Figure 32: China Viscosupplementation Market Share, by Product, 2014 149
Figure 33: India Viscosupplementation Market Share, by Product, 2014 149
Figure 34: Brazil Viscosupplementation Market Share, by Product, 2014 150
Figure 35: Global Viscosupplementation One-Injection Market Revenue ($m), by Region, 2012-2021 151
Figure 36: Global Viscosupplementation Three-Injection Market Revenue ($m), by Region, 2012-2021 152
Figure 37: Global Viscosupplementation Five-Injection Market Revenue ($m), by Region, 2012-2021 153
Figure 38: Global Viscosupplementation Market Revenue ($m), by Segment, 2012-2021 155
Figure 39: Global Viscosupplementation Market Revenue ($m), by Segment, 2014 and 2021 156
Figure 40: Global Viscosupplementation Market Revenue ($m), by Geography, 2014 and 2021 158
Figure 41: US Viscosupplementation Market Revenue ($m), 2012-2021 159
Figure 42: US Viscosupplementation Market Revenue Distribution, 2014 and 2021 160
Figure 43: France Viscosupplementation Market Revenue ($m), 2012-2021 162
Figure 44: France Viscosupplementation Market Revenue Distribution, 2014 and 2021 163
Figure 45: Germany Viscosupplementation Market Revenue ($m), 2012-2021 164
Figure 46: Germany Viscosupplementation Market Revenue Distribution, 2014 and 2021 165
Figure 47: Italy Viscosupplementation Market Revenue ($m), 2012-2021 166
Figure 48: Italy Viscosupplementation Market Revenue Distribution, 2014 and 2021 167
Figure 49: Spain Viscosupplementation Market Revenue ($m), 2012-2021 168
Figure 50: Spain Viscosupplementation Market Revenue Distribution, 2014 and 2021 169
Figure 51: UK Viscosupplementation Market Revenue ($m), 2012-2021 170
Figure 52: UK Viscosupplementation Market Revenue Distribution, 2014 and 2021 171
Figure 53: Japan Viscosupplementation Market Revenue ($m), 2012-2021 172
Figure 54: Japan Viscosupplementation Market Revenue Distribution, 2014 and 2021 173
Figure 55: Brazil Viscosupplementation Market Revenue ($m), 2012-2021 174
Figure 56: Brazil Viscosupplementation Market Revenue Distribution, 2014 and 2021 175
Figure 57: China Viscosupplementation Market Revenue ($m), 2012-2021 177
Figure 58: China Viscosupplementation Market Revenue Distribution, 2014 and 2021 178
Figure 59: India Viscosupplementation Market Revenue ($m), 2012-2021 179
Figure 60: India Viscosupplementation Market Revenue Distribution, 2014 and 2021 180
Figure 61: Breakdown of Physician Survey Participants by Geography (N=61) 196
Figure 62: Breakdown of Other Primary Research Participants by Geography (N=50) 196

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.